Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma

Journal of Clinical Oncology

Volumn 33, Issue 7, 2015, Pages 732-739

  Papadopoulos, Kyriakos P ^a   Siegel, David S ^b   Vesole, David H ^b   Lee, Peter ^c   Rosen, Steven T ^e   Zojwalla, Naseem ^d   Holahan, Joseph R ^a   Lee, Susan ^d   Wang, Zhengping ^d   Badros, Ashraf ^f  

^a South Texas Accelerated Research Therapeutics   (United States)

^b John Theurer Cancer Center   (United States)

^c Tower Cancer Research Foundation ^*  (United States)

^d ONYX PHARMACEUTICALS   (United States)

^e Northwestern Medical Center   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARFILZOMIB; CREATININE; DEXAMETHASONE; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE; PROTEASOME INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CLINICAL ARTICLE; CONFERENCE PAPER; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLATFOOT; HEART FAILURE; HUMAN; HUMAN CELL; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOXIA; INSOMNIA; JAW PAIN; KIDNEY TUBULE NECROSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE MYELOMA; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; PULMONARY HYPERTENSION; SENSORY NEUROPATHY; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEAKNESS; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEVER; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CORTEX NECROSIS; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FATIGUE; FEMALE; FEVER; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY CORTEX NECROSIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; NAUSEA; OLIGOPEPTIDES; PROTEASOME INHIBITORS; PROTEINURIA; RECURRENCE; THROMBOCYTOPENIA;

EID: 84925299376     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.3522     Document Type: Conference Paper

References (34)

1. Jagannath S, Richardson PG, Barlogie B, et al: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91: 929-934, 2006
2. Lonial S, Mitsiades CS, Richardson PG: Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 17:1264-1277, 2011
3. Laubach JP, Mitsiades CS, Mahindra A, et al: Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw 9:1209-1216, 2011
4. Kumar SK, Lee JH, Lahuerta JJ, et al: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter International Myeloma Working Group study. Leukemia 26:149-157, 2012
5. Demo SD, Kirk CJ, Aujay MA, et al: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383-6391, 2007
6. Kuhn DJ, Chen Q, Voorhees PM, et al: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110: 3281-3290, 2007
7. Kyprolis prescribing information. Onyx Pharmaceuticals, South San Francisco, CA, 2012
8. Siegel DS, Martin T, Wang M, et al: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120:2817-2825, 2012
9. Alsina M, Trudel S, Furman RR, et al: A phase I single-agent study of twice-weekly consecutiveday dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 18:4830-4840, 2012
10. Squifflet P, Michiels S, Siegel D, et al: Multivariate modelling reveals evidence of a doseresponse relationship in phase 2 studies of singleagent carfilzomib. Blood 118, 2011 (abstr 1877)
11. Hawley TS, Riz I, Yang W, et al: Identification of an ABCB1 (P-glycoprotein)-positive carfilzomibresistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol 88:265-272, 2013
12. Yang J, Wang Z, Fang Y, et al: Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 39:1873-1882, 2011
13. Jiang J, Kirk C, Muchamuel T, et al: The benefits of irreversibility: Infusion administration of carfilzomib results in potent proteasome inhibition and improved safety in animals. Cancer Res 71, 2011 (abstr 2607)
14. Common Terminology Criteria for Adverse Events, version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
15. Papadopoulos KP, Burris HA 3rd, Gordon M, et al: A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 72:861-868, 2013
16. Jakubowiak AJ, Dytfeld D, Griffith KA, et al: A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120:1801-1809, 2012
17. Vij R, Wang M, Kaufman JL, et al: An openlabel, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119:5661-5670, 2012
18. Jagannath S, Vij R, Stewart AK, et al: An openlabel single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 12:310-318, 2012
19. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006
20. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT - European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
21. Rajkumar SV, Harousseau JL, Durie B, et al: Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 117: 4691-4695, 2011
22. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
23. Moreau P, Richardson PG, Cavo M, et al: Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120:947-959, 2012
24. Richardson P, Jagannath S, Hussein M, et al: Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114:772-778, 2009
25. Richardson PG, Siegel D, Baz R, et al: Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121: 1961-1967, 2013
26. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142, 2007
27. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132, 2007
28. Lacy MQ, Hayman SR, Gertz MA, et al: Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 24:1934-1939, 2010
29. Vij R, Siegel DS, Jagannath S, et al: An openlabel, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 158:739-748, 2012
30. Siegel D, Martin T, Nooka A, et al: Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98:1753-1761, 2013
31. Lendvai N, Landau H, Lesokhin A, et al: Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma. Blood 120, 2012 (abstr 947)
32. Armenian SH, Sun CL, Vase T, et al: Cardiovascular risk factors in hematopoietic cell transplantation survivors: Role in development of subsequent cardiovascular disease. Blood 120:4505-4512, 2012
33. Papadopoulos K, Lee P, Singhal S, et al: PPX-171-007: A phase 1b study evaluating the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma (MM). Haematologica 96, 2011 (abstr 0898)
34. Lee S, Arastu-Kapur S, Kellerman L, et al: Potent inhibition of selective proteasome subunits by carfilzomib in multiple myeloma and solid tumor patients is associated with patients response. Haematologica 97, 2012 (abstr 0840)